ARCA Biopharma Announces Issuance of European Patent for Treating Cardiovascular Diseases and Conditions With a New Chemical Entity Utilizing Genetic Targeting
November 16, 2017 08:30 ET
|
ARCA biopharma, Inc.
WESTMINSTER, Colo., Nov. 16, 2017 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq:ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted...
Tempus Announces Latest Immunotherapy Project
November 15, 2017 10:15 ET
|
Tempus
CHICAGO, Nov. 15, 2017 (GLOBE NEWSWIRE) -- Tempus, a technology company focused on helping doctors personalize cancer care by collecting and analyzing large volumes of molecular and clinical data,...
Tempus and Sanford Health Collaborate on Personalized Medicine Initiative
November 01, 2017 10:15 ET
|
Tempus
CHICAGO, Nov. 01, 2017 (GLOBE NEWSWIRE) -- Tempus, a rapidly-growing technology company focused on collecting and integrating molecular and clinical data and Sanford Health, one of the largest...
Tempus Unveils Tempus xT, 595 Gene Panel Aimed at Empowering Data-Driven Cancer Care
October 19, 2017 10:30 ET
|
Tempus
CHICAGO, Oct. 19, 2017 (GLOBE NEWSWIRE) -- Tempus today announced the launch of its new comprehensive genomic sequencing panel, Tempus xT, which analyzes 595 genes relevant to the diagnosis,...
Cancer Genetics, Inc. to Host Panel Discussion on “The Convergence of Artificial Intelligence and Healthcare - New Developments in Precision Medicine” During the 3rd Annual Dawson James Small Cap Growth Conference on October 18th
October 12, 2017 07:30 ET
|
Cancer Genetics, Inc.
Cancer Genetics Will Also Present a Corporate Overview on Thursday, October 19th RUTHERFORD, N.J., Oct. 12, 2017 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq:CGIX) (“CGI” or “The Company”), a...
Tempus and the OHSU Knight Cancer Institute Collaborating on Personalized Medicine Data Initiative
September 28, 2017 10:00 ET
|
Tempus
CHICAGO, Sept. 28, 2017 (GLOBE NEWSWIRE) -- Tempus, a technology company focused on helping doctors personalize cancer care by collecting and analyzing large volumes of molecular and clinical data,...
Tempus Announces $130M Raised
September 25, 2017 09:00 ET
|
Tempus
CHICAGO, Sept. 25, 2017 (GLOBE NEWSWIRE) -- Tempus announced today that it closed a $70M, Series C, round of venture funding co-led by New Enterprise Associates (NEA) and Revolution Growth. This...
Tempus and Cleveland Clinic Collaborate on Personalized Medicine Initiative
September 14, 2017 10:30 ET
|
Tempus
CHICAGO, Sept. 14, 2017 (GLOBE NEWSWIRE) -- Tempus, a technology company focused on helping doctors personalize cancer care by collecting and analyzing large volumes of molecular and clinical data,...
Metabolon Acquires Metabolomic Discoveries GmbH
September 05, 2017 09:41 ET
|
Metabolon, Inc.
RESEARCH TRIANGLE PARK, N.C., Sept. 05, 2017 (GLOBE NEWSWIRE) -- Metabolon, Inc., the global leader in metabolomics, announced today the acquisition of Metabolomic Discoveries GmbH, a leading...
Tempus and University of California Davis Comprehensive Cancer Center Announce Personalized Medicine Partnership for Cancer Patients
August 31, 2017 10:00 ET
|
Tempus
CHICAGO, Aug. 31, 2017 (GLOBE NEWSWIRE) -- Tempus, a technology company focused on helping doctors personalize cancer care by collecting and analyzing large volumes of molecular and clinical data...